MCID: HYP011
MIFTS: 41

Hyperlipoproteinemia Type Iii malady

Categories: Genetic diseases, Metabolic diseases, Endocrine diseases, Rare diseases

Aliases & Classifications for Hyperlipoproteinemia Type Iii

About this section

Aliases & Descriptions for Hyperlipoproteinemia Type Iii:

Name: Hyperlipoproteinemia Type Iii 11 49 38 13 67
Familial Hypercholesterolaemia with Hyperlipaemia 11
Familial Type 3 Hyperlipoproteinemia 11
 
Familial Hyperlipoproteinemia Type 3 26
Carbohydrate Induced Hyperlipemia 11
Remnant Hyperlipidemia 11

Classifications:



External Ids:

Disease Ontology11 DOID:3145
MeSH38 D006952
SNOMED-CT61 398796005, 42569002
NCIt44 C34710

Summaries for Hyperlipoproteinemia Type Iii

About this section
MalaCards based summary: Hyperlipoproteinemia Type Iii, also known as familial hypercholesterolaemia with hyperlipaemia, is related to hyperlipidemia type 3 and hyperchylomicronemia, late-onset. An important gene associated with Hyperlipoproteinemia Type Iii is APOE (Apolipoprotein E), and among its related pathways are A-beta Pathways: Uptake and Degradation and Vitamin digestion and absorption. Related mouse phenotypes are liver/biliary system and homeostasis/metabolism.

Related Diseases for Hyperlipoproteinemia Type Iii

About this section

Diseases in the Hyperlipoproteinemia, Type Ib family:

Hyperlipoproteinemia, Type 1d Hyperlipoproteinemia Type Iv
hyperlipoproteinemia type iii

Diseases related to Hyperlipoproteinemia Type Iii via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50)    (show all 65)
idRelated DiseaseScoreTop Affiliating Genes
1hyperlipidemia type 311.8
2hyperchylomicronemia, late-onset11.1
3hyperlipoproteinemia type iv11.1
4cardiovascular disease risk factor )10.9
5dysmorphism-pectus carinatum-joint laxity syndrome10.5APOB, APOE
6atp1a3-related neurologic disorders10.5APOE, LPL
7respiratory syncytial virus infectious disease10.4APOE, LPA
8casr-related disorders10.4APOB, APOE
9spondylometaphyseal dysplasia, megarbane-dagher-melike type10.3LIPC, LPL
10hypercholesterolemia, due to ligand-defective apo b10.3APOB, APOE, LDLR
11arthritis10.3APOE, LDLR, LPA
12hypobetalipoproteinemia10.3APOB, APOE, LDLR
13c1s deficiency10.2APOA5, APOE, LPL
14limb-girdle muscular dystrophy10.2APOA1, APOA5
15peripheral degeneration of cornea10.2APOB, APOE, COG2
16alzheimer disease 19, late onset10.1APOB, APOE, LDLR, LPA
17shwachman-diamond type metaphyseal dysplasia10.1APOA1, APOB
18fetal methyl mercury syndrome10.0APOA1, APOB
19angiomatous meningioma10.0APOB, COG2, LPL
20orbital margin, hypoplasia of10.0COG2, MGAM
21gemistocytic astrocytoma9.9APOA1, APOB, APOE
22legg-calve-perthes disease9.9APOA1, APOB
23polyneuropathy9.9APOA1, APOB, APOE, LPA
24blue toe syndrome9.9APOA5, APOB, LIPC, LPL
25stroke, ischemic9.9APOB, APOE, COG2, LPA
26littre gland carcinoma9.9APOA1, APOB, APOE, LPA
27tracheal calcification9.9APOA1, APOB, COG2
28pyelonephritis9.9APOA5, APOB, APOE, CETP
29islet cell tumor9.9APOA1, APOB, APOE, LPL
30posterior foramen magnum meningioma9.9APOA1, APOB, COG2
31bone angioendothelial sarcoma9.8APOB, HMGCR, LPA
32amelogenesis imperfecta, type iia39.8APOA1, APOE, LIPC, LPL
33macular degeneration, age-related, 19.8APOB, APOE, CETP, LIPC
34survival motor neuron spinal muscular atrophy9.8APOA1, APOB, COG2
35hemochromatosis, type 59.8APOE, HMGCR, LDLR
36pontocerebellar hypoplasia9.8APOA1, APOB, APOE, CETP
37flat retinoschisis9.8APOB, HMGCR
38conjunctival disease9.8APOA1, APOE, CETP, LPL
39angina pectoris9.7APOA1, APOB, COG2, LPA
40degos 'en cocarde' erythrokeratoderma9.6APOB, APOE, HMGCR, LDLR
41obesity, hyperphagia, and developmental delay9.6APOA1, APOB, APOE, CETP, LPA
42glossopharyngeal nerve neoplasm9.5APOA1, APOB, APOE, COG2, LPA
43wolfram syndrome 29.5APOA1, APOB, APOE, CETP, LPL
44retinal arteries, tortuosity of9.5APOE, HMGCR
45dermal unilateral segmental cavernous angioma9.4APOB, APOE, LPA, MGAM, SERPINB6
46von willebrand disease, platelet-type9.4APOA1, APOB, APOE, LDLR, LPA, LPL
47hepatic adenoma, somatic9.4APOA1, APOB, COG2, LPA, LPL
48chondrocalcinosis with early-onset osteoarthritis9.3APOA1, APOB, APOE, CETP, LPA, LPL
49bladder diverticulum9.3APOA1, APOB, APOE, COG2, LDLR, LPA
50cataract 5, multiple types9.2APOA1, APOB, CETP, LDLR, LIPC, LPL

Graphical network of the top 20 diseases related to Hyperlipoproteinemia Type Iii:



Diseases related to hyperlipoproteinemia type iii

Symptoms for Hyperlipoproteinemia Type Iii

About this section

Drugs & Therapeutics for Hyperlipoproteinemia Type Iii

About this section

Drugs for Hyperlipoproteinemia Type Iii (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show all 25)
idNameStatusPhaseClinical TrialsCas NumberPubChem Id
1Anticholesteremic AgentsPhase 4, Phase 31983
2Lipid Regulating AgentsPhase 4, Phase 32702
3Hypolipidemic AgentsPhase 4, Phase 32721
4AntimetabolitesPhase 4, Phase 311774
5Colesevelam HydrochloridePhase 447
6
FosamprenavirapprovedPhase 377226700-79-4131536
Synonyms:
((3S)Oxolan-3-yloxy)-N-((1S,2R)-3-{[(4-aminophenyl)sulfonyl](2-methylpropyl)amino}-1-benzyl-2-(phosphonooxy)propyl)carboxamide
(3-(((4-Aminophenyl)sulfonyl)(2-methylpropyl)amino)-1-(phenylmethyl)-2-(phosphonooxy)propyl)carbamic acid C-(tetrahydro-3-furanyl) ester
226700-79-4
AC1L2ZCO
Amprenavir phosphate
CHEMBL1664
CID131536
Carbamic acid, ((1S,2R)-3-(((4-aminophenyl)sulfonyl)(2-methylpropyl)amino)-1-(phenylmethyl)-2-(phosphonooxy)propyl)-, C-((3S)-tetrahydro-3-furanyl) ester
D02497
DB01319
Fosamprenavir
Fosamprenavir (INN)
Fosamprenavir [INN]
 
GW 433908
GW433908
GW433908A (*Sodium Salt*)
GW433908G (*Calcium Salt*)
HSDB 7340
LS-187013
LS-187787
Lexiva
Lexiva (TM)
MolPort-005-943-058
Telzir
Telzir(TM)
VX 175
VX-175
[(3S)-oxolan-3-yl] N-[(2S,3R)-4-[(4-aminophenyl)sulfonyl-(2-methylpropyl)amino]-1-phenyl-3-phosphonooxybutan-2-yl]carbamate
7
SimvastatinapprovedPhase 351079902-63-954454
Synonyms:
(+)-Simvastatin
(1S,3R,7S,8S,8aR)-8-{2-[(2R,4R)-4-hydroxy-6-oxotetrahydro-2H-pyran-2-yl]ethyl}-3,7-dimethyl-1,2,3,7,8,8a-hexahydronaphthalen-1-yl 2,2-dimethylbutanoate
2,2-Dimethylbutanoic acid (1S,3R,7S,8S,8aR)-1,2,3,7,8,8a-hexahydro-3,7-dimethyl-8-[2-[(2R,4R)-tetrahydro-4-hydroxy-6-oxo-2H-pyran-2-yl]ethyl]-1-naphthalenyl ester
2,2-Dimethylbutyric acid, 8-ester with (4R,6R)-6-(2-((1S,2S,6R,8S,8aR)-1,2,6,7,8,8a-hexahydro-8-hydroxy-2,6-dimethyl-1-naphthyl)ethyl)tetrahydro-4-hydroxy-2H-pyran-2-one
2,2-Dimethylbutyric acid, 8-ester with (4R,6R)-6-(2-((1S,2S,6R,8S,8ar)-1,2,6,7,8,8a-hexahydro-8-hydroxy-2,6-dimethyl-1-naphthyl)ethyl)tetrahydro-4-hydroxy-2H-pyran-2-one
79902-63-9
AC-1530
AC1L1H1F
AKOS005111006
ARONIS24119
BCBcMAP01_000007
BIDD:GT0769
BPBio1_001001
BRD-K22134346-001-05-8
BRN 4768037
BSPBio_000909
BSPBio_002337
Bio-0672
Butanoic acid, 2,2-dimethyl-, (1S,3R,7S,8S,*aR)-1,2,3,7,8,8a-hexahydro-3,7-dimethyl-8-(2-((2R,4R)-tetrahydro-4-hydroxy-6-oxo-2H-pyran-2-yl)ethyl)-1-naphthalenyl ester
Butanoic acid, 2,2-dimethyl-, (1S,3R,7S,8S,8aR)-1,2,3,7,8,8a-hexahydro-3,7-dimethyl-8-(2-((2R,4R)-tetrahydro-4-hydroxy-6-oxo-2H-pyran-2-yl)ethyl)-1-naphthalenyl ester
Butanoic acid, 2,2-dimethyl-, (1S,3R,7S,8S,8aR)-1,2,3,7,8,8a-hexahydro-3,7-dimethyl-8-[2-[(2R,4R)-tetrahydro-4-hydroxy-6-oxo-2H-pyran-2-yl]ethyl]-1-naphthalenyl ester
C25H38O5
CCRIS 7558
CHEBI:9150
CHEMBL1064
CID54454
CPD000718785
Cholestat
Coledis
Colemin
Corolin
D00434
D019821
DRG-0320
Denan
DivK1c_006991
Eucor
HMS1570N11
HMS1922H13
HMS2089D12
HMS2093E06
HSDB 7208
InChI=1/C25H38O5/c1-6-25(4,5)24(28)30-21-12-15(2)11-17-8-7-16(3)20(23(17)21)10-9-19-13-18(26)14-22(27)29-19/h7-8,11,15-16,18-21,23,26H,6,9-10,12-14H2,1-5H3/t15-,16-,18+,19+,20-,21-,23-/m0/s1
KBio1_001935
KBio2_002197
KBio2_004765
KBio2_007333
KBio3_001557
KBioGR_001244
KBioSS_002197
KS-1113
Kolestevan
L 644128-000U
LS-46264
Labistatin
Lipex
Lipinorm
Liponorm
Lipovas
Lodales
MK 0733
MK 733
MK-0733
MK-733
MK733
MLS001304029
MLS001333077
MLS001333078
 
MLS002154038
Medipo
Modutrol
MolPort-002-507-345
MolPort-002-885-862
NCGC00017324-01
NCGC00017324-02
NCGC00017324-03
Nivelipol
Nor-Vastina
Pantok
Pepstatin
Prestwick0_000865
Prestwick1_000865
Prestwick2_000865
Prestwick3_000865
Prestwick_171
Rechol
Rendapid
S1792_Selleck
S6196_SIGMA
SAM002589969
SMR000718785
SPBio_001881
SPBio_002830
SPECTRUM1504236
STK801938
Simcor
Simovil
Simvast CR
Simvastatin
Simvastatin & Primycin
Simvastatin (JAN/USP/INN)
Simvastatin [USAN:INN:BAN]
Simvastatin [Usan:Ban:Inn]
Simvastatin lactone
Simvastatin, Compactin
Simvastatina
Simvastatina [Spanish]
Simvastatine
Simvastatine [French]
Simvastatinum
Simvastatinum [Latin]
Simvotin
Sinvacor
Sinvascor
Sivastin
SpecPlus_000895
Spectrum2_001671
Spectrum3_000669
Spectrum4_000632
Spectrum5_001428
Spectrum_001717
Statin
Synvinolin
TNP00259
UNII-AGG2FN16EV
Valemia
Vasotenal
Velostatin
Vytorin
ZINC03780893
Zocor
Zocor (TN)
Zocor, Simlup, Simcard, Simvacor, Simvoget, Zorced, Simvastatin
Zocord
[(1S,3R,7S,8S,8aR)-8-[2-[(2R,4R)-4-hydroxy-6-oxooxan-2-yl]ethyl]-3,7-dimethyl-1,2,3,7,8,8a-hexahydronaphthalen-1-yl] 2,2-dimethylbutanoate
butanoic acid, 2,2-dimethyl-,1,2,3,7,8,8a-hexahydro-3,7-dimethyl-8-[2-(tetrahydro-4-hydroxy-6-oxo-2H-pyran-2-yl)-ethyl]-1-naphthalenyl ester, [1S-[1 alpha,3 alpha,7 beta,8 beta(2S*,4S*),-8a beta
nchembio790-comp16
simvastatin
8
FluvastatinapprovedPhase 35893957-54-11548972
Synonyms:
(+)-(3R,5S)-fluvastatin
(-)-(3S,5R)-fluvastatin
(3R,5R,6E)-7-[3-(4-fluorophenyl)-1-(propan-2-yl)-1H-indol-2-yl]-3,5-dihydroxyhept-6-enoic acid
(3R,5R,6E)-7-[3-(4-fluorophenyl)-1-isopropyl-1H-indol-2-yl]-3,5-dihydroxyhept-6-enoic acid
(3R,5S)-7-[3-(4-fluorophenyl)-1-propan-2-ylindol-2-yl]-3,5-dihydroxyhept-6-enoic acid
(3R,5S,6E)-7-[3-(4-fluorophenyl)-1-(1-methylethyl)-1H-indol-2-yl]-3,5-dihydroxyhept-6-enoic acid
(3R,5S,6E)-7-[3-(4-fluorophenyl)-1-(propan-2-yl)-1H-indol-2-yl]-3,5-dihydroxyhept-6-enoic acid
(3R,5S,6E)-7-[3-(4-fluorophenyl)-1-isopropyl-1H-indol-2-yl]-3,5-dihydroxyhept-6-enoic acid
(3R,5S,6E)-rel-7-[3-(4-Fluorophenyl)-1-(1-methylethyl)-1H-indol-2-yl]-3,5-dihydroxy-6-heptenoic acid
(3S,5R,6E)-7-[3-(4-fluorophenyl)-1-(propan-2-yl)-1H-indol-2-yl]-3,5-dihydroxyhept-6-enoic acid
(3S,5R,6E)-7-[3-(4-fluorophenyl)-1-isopropyl-1H-indol-2-yl]-3,5-dihydroxyhept-6-enoic acid
(6E)-7-[3-(4-fluorophenyl)-1-(propan-2-yl)-1H-indol-2-yl]-3,5-dihydroxyhept-6-enoic acid
(6E)-7-[3-(4-fluorophenyl)-1-isopropyl-1H-indol-2-yl]-3,5-dihydroxyhept-6-enoic acid
(E)-7-[3-(4-fluorophenyl)-1-propan-2-ylindol-2-yl]-3,5-dihydroxyhept-6-enoic acid
(E,3R,5S)-7-[3-(4-fluorophenyl)-1-propan-2-ylindol-2-yl]-3,5-dihydroxyhept-6-enoic acid
(E,3S,5R)-7-[3-(4-fluorophenyl)-1-propan-2-ylindol-2-yl]-3,5-dihydroxyhept-6-enoic acid
(Z,3R,5S)-7-[3-(4-fluorophenyl)-1-propan-2-ylindol-2-yl]-3,5-dihydroxyhept-6-enoic acid
7-(3-(4-fluorophenyl)-1-(1-methylethyl)-1H-indol-2-yl)-3,5-dihydroxy-6-heptenoate
7-[3-(4-fluorophenyl)-1-propan-2-ylindol-2-yl]-3,5-dihydroxyhept-6-enoic acid
93957-54-1
AC1L1FUW
AC1L3TXK
AC1L9J7I
AC1LU7LJ
AC1NS4EB
AC1OC9O5
AC1Q1PZO
BIDD:GT0839
BPBio1_000965
BRD-K03602135-236-02-1
BSPBio_000877
C07014
C24H26FNO4
CHEBI:38562
CHEBI:38565
CHEBI:38567
CHEBI:5136
CHEMBL1078
CHEMBL170417
CID10501876
CID146801
CID1548972
 
CID3403
CID446155
CID5353627
CID6914285
CID9887837
CPD001453708
Canef
Cranoc
D07983
DB01095
Fluindostatin
Fluvas
Fluvas (TN)
Fluvastatin & Primycin
Fluvastatin (INN)
Fluvastatin [INN:BAN]
Fluvastatina
Fluvastatina [INN-Spanish]
Fluvastatine
Fluvastatine [INN-French]
Fluvastatinum
Fluvastatinum [INN-Latin]
HMS2089P06
I06-2297
LS-7404
Lescol
Lescol XL
MolPort-003-847-470
Prestwick0_000859
Prestwick1_000859
Prestwick2_000859
Prestwick3_000859
SAM002548940
SPBio_002798
T6624179
TL8005940
UNII-4L066368AS
XU 62320
XU-62320
fluvastatin
fluvastatin sodium
nchembio.301-comp9
nchembio790-comp18
9
PitavastatinapprovedPhase 365147511-69-1, 147526-32-76366718, 5282452
Synonyms:
( )-(3R,5S,6E)-7-(2-Cyclopropyl-4-(4-fluorophenyl)-3-quinolyl)-3,5-dihydroxy-6-heptenoic acid
(3R,5S,6E)-7-(2-Cyclopropyl-4-(4-fluorophenyl)quinolin-3-yl)-3,5-dihydroxyhept-6-enoic acid
(3R,5S,6E)-7-(2-Cyclopropyl-4-(p-fluorophenyl)-3-quinolyl)-3,5-dihydroxy-6-heptenoic acid
(3R,5S,E)-7-(2-cyclopropyl-4-(4-fluorophenyl)quinolin-3-yl)-3,5-dihydroxyhept-6-enoate
(E,3R,5S)-7-[2-cyclopropyl-4-(4-fluorophenyl)quinolin-3-yl]-3,5-dihydroxyhept-6-enoic acid
111GE002
147511-69-1
147526-32-7
2C25H23FNO4.Ca
AC1NR03G
AC1NR03J
AKOS005145916
Alipza
Bis((3R,5S,6E)-7-(2-cyclopropyl-4-(4-fluorophenyl)-3-quinolyl)-3,5-dihydroxy-6-heptenoate), monocalcium salt
C13334
CCRIS 8652
CID5282451
CID5282452
D01862
Itavastatin
Itavastatin calcium
KS-1220
LS-190698
 
LS-74594
LS-74595
Livalo
Livalo (TN)
Livalo, Pitavastatin calcium
Livazo
MolPort-006-822-984
NK 104
NK-104
NKS-104
Nisvastatin
P 872441
P-872441
Pitavastatia
Pitavastatin
Pitavastatin [INN]
Pitavastatin calcium
Pitavastatin calcium (JAN)
Pitavastatin hemicalcium
Pitavastatine
Pitavastatinum
S1759_Selleck
ZINC01534965
calcium (E,3R,5S)-7-[2-cyclopropyl-4-(4-fluorophenyl)quinolin-3-yl]-3,5-dihydroxyhept-6-enoate
10
PravastatinapprovedPhase 314981093-37-054687
Synonyms:
(+)-(3R,5R)-3,5-Dihydroxy-7-[(1S,2S,6S,8S,8ar)-6-hydroxy-2-methyl-8-{[(S)-2-methylbutyryl]oxy}-1,2,6,7,8,8a-hexahydro-1-naphthyl]heptanoic acid
(3R,5R)-3,5-dihydroxy-7-[(1S,2S,6S,8S,8aR)-6-hydroxy-2-methyl-8-{[(2S)-2-methylbutanoyl]oxy}-1,2,6,7,8,8a-hexahydronaphthalen-1-yl]heptanoic acid
(3R,5R)-7-[(1S,2S,6S,8S,8aR)-6-hydroxy-2-methyl-8-[(2S)-2-methylbutanoyl]oxy-1,2,6,7,8,8a-hexahydronaphthalen-1-yl]-3,5-dihydroxyheptanoic acid
1,2,6,7,8,8a-hexahydro-beta,delta,6-trihydroxy-2-methyl-8-(2-methyl-1-oxobutoxy)-, (1S-(1alpha(betaS*,deltaS*),2alpha,6alpha,8beta(R*),8aalpha))-1-Naphthaleneheptanoic acid
3beta-Hydroxycompactin
81093-37-0
81131-70-6 (hydrochloride salt)
AC1L1HJL
AC1Q5T3M
BIDD:GT0773
BRD-K60511616-236-01-4
C01844
C23H36O7
CCRIS 7557
CHEMBL1144
CID54687
Compactin
D08410
DB00175
Elisor
Eptastatin
FT-0082682
KS-5015
LS-94713
Lipostat
Mevalothin
Mevalotin
Mevastatin
Mevinolin
 
Oliprevin
Pravachol
Pravaselect
Pravastatin (INN)
Pravastatin Sodium
Pravastatin Sodium Salt
Pravastatin [INN:BAN]
Pravastatin acid
Pravastatin sodium
Pravastatin tert-Octylamine Salt
Pravastatina
Pravastatina [Spanish]
Pravastatine
Pravastatine [French]
Pravastatinum
Pravastatinum [Latin]
Pravator
Pravator (TN)
RMS-431
SQ-31,000
Selectin
Selektine
Selipran
UNII-KXO2KT9N0G
Vasten
nchembio.301-comp7
nchembio790-comp15
pravastatin
pravastatina
pravastatine
pravastatinum
11
EzetimibeapprovedPhase 3272163222-33-1150311
Synonyms:
(-)-Sch 58235
(1-(4-fluorophenyl)-(3R)-(3-(4-fluorophenyl)-(3S)-hydroxypropyl)-(4S)-(4-hydroxyphenyl)-2-azetidinone)
(3R,4S)-1-(4-fluorophenyl)-3-[(3S)-3-(4-fluorophenyl)-3-hydroxypropyl]-4-(4-hydroxyphenyl)azetidin-2-one
(3R,4S)-1-(p-Fluorophenyl)-3-((3S)-3-(p-fluorophenyl)-3-hydroxypropyl)-4-(p-hydroxyphenyl)-2-azetidinone
1-(4-fluorophenyl)-3(R)-[3-(4-fluorophenyl)-3(S)-(4-hydroxyphenyl)-2-azetidione
1-(4-fluorophenyl)-3(R)-[3-(4-fluorophenyl)-3(S)-hydroxypropyl]-4(S)-(4-hydroxyphenyl)-2-azetidinone
163222-33-1
AC-1057
AC1L442L
C108606
CHEBI:49040
CHEMBL1138
CID150311
CPD000466334
D01966
DB00973
Essex brand of ezetimibe
Ezedoc
Ezetimiba
Ezetimibe
Ezetimibe (JAN/USAN/INN)
Ezetimibe [USAN:INN]
Ezetimibum
 
Ezetrol
HMS2051K16
LS-181801
MK-0653
MLS000759443
MLS001424125
MSD brand of ezetimibe
Merck brand of ezetimibe
MolPort-005-938-627
S1655_Selleck
SAM001246623
SCH-58235
SCH58235
SMR000466334
STK640490
STOCK6S-73750
Sch 58235
Schering-Plough brand of ezetimibe
UNII-EOR26LQQ24
ZINC03810860
Zetia
Zetia (TN)
Zetia , Ezetrol, Ezetimibe
Zient
ezetimib
12
FenofibrateapprovedPhase 316949562-28-93339
Synonyms:
2-(4-(4-Chlorobenzoyl)phenoxy)-2-methylpropanoic acid 1-methylethyl ester
49562-28-9
AB00052196
AC-4227
AC1L1FPK
AKOS005107777
AZU, Fenofibrat
AbZ Brand of Procetofen
Abbott Brand of Procetofen
Aliud Brand of Procetofen
Ankebin
Antara
Antara (TN)
Antara (micronized)
Antara Micronized Procetofen
Anto Brand of Procetofen
Apo Feno Micro
Apo Fenofibrate
Apo-Feno-Micro
Apo-Fenofibrate
Apotex Brand of Procetofen
Azupharma Brand of Procetofen
BIDD:GT0574
BPBio1_000166
BRD-K50388907-001-05-6
BRN 2062462
BSPBio_000150
BSPBio_003162
Bouchara Brand of Procetofen
C07586
C20H21ClO4
CAS-49562-28-9
CCRIS 7282
CHEBI:5001
CHEMBL672
CID3339
CIP-Fenofibrate
CPD000058299
Controlip
D00565
D011345
DB01039
Debat, Fenofibrate
DivK1c_000557
EINECS 256-376-3
EU-0100486
Elasterate
Elasterin
F 6020
F6020_SIGMA
FENOFIBRATE (MICRONIZED)
FNF
Fenobeta
Fenobrate
Fenofanton
Fenofibrat AL
Fenofibrat AZU
Fenofibrat AbZ
Fenofibrat FPh
Fenofibrat Heumann
Fenofibrat Hexal
Fenofibrat Stada
Fenofibrat ratiopharm
Fenofibrat-ratiopharm
Fenofibrate
Fenofibrate (JAN/INN)
Fenofibrate Debat
Fenofibrate IDD-P
Fenofibrate MSD
Fenofibrate [INN:BAN]
Fenofibrato
Fenofibrato [INN-Spanish]
Fenofibratum
Fenofibratum [INN-Latin]
Fenofibric acid
Fenogal
Fenoglide
Fenomax
Fenotard
Finofibrate
Fournier Brand of Procetofen
Fulcro
GNR Pharma Brand of Procetofen
GNR-Pharma Brand of Procetofen
GRS-027
Gate Brand of Procetofen
Gen Fenofibrate
Gen-Fenofibrate
Genpharm Brand of Procetofen
HMS1568H12
HMS1921B17
HMS2090G20
HMS2092B05
HMS501L19
Heumann Brand of Procetofen
Heumann, Fenofibrat
Hexal Brand of Procetofen
Hexal, Fenofibrat
I06-0048
IDI1_000557
Isopropyl (4'-(P-chlorobenzoyl)-2-phenoxy-2-methyl)propionate
Isopropyl 2-(4-(4-chlorobenzoyl)phenoxy)-2-methylpropionate
Isopropyl 2-(p-(p-chlorobenzoyl)phenoxy)-2-methylpropionate
KBio1_000557
KBio2_001730
KBio2_004298
KBio2_006866
KBio3_002382
KBioGR_000706
KBioSS_001730
Knoll Brand of Procetofen
LCP-Feno
LCP-FenoChol
LF 178
 
LF-178
LF178
LS-121256
Lichtenstein Brand of Procetofen
Lipanthyl
Lipantil
Lipantil (TN)
Liparison
Lipidex
Lipidil
Lipidil Micro
Lipidil Supra
Lipidil Ter
Lipidil-Ter
Lipifen
Lipirex
Lipoclar
Lipofen
Lipofen (TN)
Lipofene
Liposit
Lipsin
Lofibra
Lopac-F-6020
Lopac0_000486
Luxacor
MLS000028515
MLS001148191
MTW Brand of Procetofen
MTW Fenofibrat
MTW-Fenofibrat
Merck dura Brand of Procetofen
Micronized Procetofen, Antara
MolPort-002-887-051
NCGC00015437-01
NCGC00015437-02
NCGC00015437-03
NCGC00015437-06
NCGC00015437-12
NCGC00021475-03
NCGC00021475-04
NCGC00021475-05
NCGC00021475-06
NCGC00021475-07
NCGC00021475-08
NINDS_000557
NSC 281319
NSC281319
Nolipax
Novartis Brand of Procetofen
Novo Fenofibrate
Novo-Fenofibrate
Novopharm Brand of Procetofen
Nu Fenofibrate
Nu Pharm Brand of Procetofen
Nu-Fenofibrate
Nu-Pharm Brand of Procetofen
PMS Fenofibrate Micro
PMS-Fenofibrate Micro
Pharmascience Brand of Procetofen
Pharmavit
Phenofibrate
Prestwick0_000275
Prestwick1_000275
Prestwick2_000275
Prestwick3_000275
Prestwick_217
Procetofen
Procetofen Reliant Brand
Procetofen, Antara Micronized
Procetofene
Proctofene
Protolipan
Q Pharm Brand of Procetofen
Q-Pharm Brand of Procetofen
Reliant Brand of Procetofen
S1794_Selleck
SAM002264613
SMR000058299
SPBio_001380
SPBio_002369
SPECTRUM1501010
ST085313
Schering Plough Brand of Procetofen
Schering-Plough Brand of Procetofen
Secalip
Sedufen
Spectrum2_001390
Spectrum3_001431
Spectrum4_000413
Spectrum5_001479
Spectrum_001250
Stada, Fenofibrat
Stadapharm Brand of Procetofen
Supralip
TL8003296
TRICOR (MICRONIZED)
Tricor
Tricor (TN)
Triglide
Triglide (TN)
Trilipix
UNII-U202363UOS
United Drug Brand of Procetofen
ZINC00584092
betapharm Brand of Procetofen
ct Arzneimittel Brand of Procetofen
ct-Arzneimittel Brand of Procetofen
durafenat
fenofibrat von ct
fenofibrate
fenofibric acid
isopropyl 2-[4-(4-chlorobenzoyl)phenoxy]-2-methylpropanoate
nchembio790-comp24
ratiopharm Brand of Procetofen
13Calcium, DietaryPhase 35525
14Pharmaceutical SolutionsPhase 37793
15Atorvastatin CalciumPhase 3743134523-03-8
16ImmunoglobulinsPhase 36045
17Rosuvastatin CalciumPhase 3459147098-20-2
18Hydroxymethylglutaryl-CoA Reductase InhibitorsPhase 3, Phase 21956
19AntibodiesPhase 36045
20Antibodies, MonoclonalPhase 33795
21
TorcetrapibPhase 315262352-17-0159325
Synonyms:
(2R,4S)-4-((3,5-Bis-trifluoromethylbenzyl)methoxycarbonylamino)-2-ethyl-6-trifluoromethyl-3,4-dihydro-2H-quinoline-1-carboxylic acid ethyl ester
262352-17-0
AC1L4LN3
CHEBI:49203
CHEBI:617982
CHEMBL479527
CID159325
CP 529414
CP-529,414
 
CP-529414
D06195
Ethyl (2R,4S)-4-((3,5-bis(trifluoromethyl)benzyl)(methoxycarbonyl)amino)-2-ethyl-6-(trifluoromethyl)-3,4-dihydroquinoline-1(2H)-carboxylate
LS-187027
LS-187649
Torcetrapib
Torcetrapib (USAN/INN)
Torcetrapib [USAN]
ethyl (2R,4S)-4-[[3,5-bis(trifluoromethyl)phenyl]methyl-methoxycarbonylamino]-2-ethyl-6-(trifluoromethyl)-3,4-dihydro-2H-quinoline-1-carboxylate
ethyl (2R,4S)-4-{[3,5-bis(trifluoromethyl)benzyl](methoxycarbonyl)amino}-2-ethyl-6-(trifluoromethyl)-3,4-dihydroquinoline-1(2H)-carboxylate
22Trace ElementsPhase 25802
23
CobaltPhase 21657440-48-4104729
Synonyms:
Aquacat
Co
 
Cobalt-59
Cobatope-57
Kobalt
Super cobalt
24MicronutrientsPhase 25802
25PhytosterolNutraceutical115

Interventional clinical trials:

(show all 19)
idNameStatusNCT IDPhase
1A Study of the Safety and Efficacy of Patients With Familial Hypercholesterolaemia Taking Colesevelam as add-on Therapy to Their Existing MedicationCompletedNCT00655265Phase 4
2Type III DysbetalipoproteinemiaCompletedNCT00214604Phase 3
3A Safety and Efficacy Study of AEGR-733 to Treat Homozygous Familial Hypercholesterolemia (FH)CompletedNCT00730236Phase 3
4Long Term, Follow-on Study of Lomitapide in Patients With Homozygous Familial HypercholesterolemiaCompletedNCT00943306Phase 3
5A Randomized, Double-blind, Placebo Controlled Study to Assess Efficacy, Safety and Tolerability of LCQ908 in Subjects With Familial Chylomicronemia SyndromeCompletedNCT01514461Phase 3
6Efficacy and Safety Evaluation of Alirocumab in Patients With Heterozygous Familial Hypercholesterolemia or High Cardiovascular Risk Patients With Hypercholesterolemia on Lipid Modifying Therapy (ODYSSEY JAPAN)CompletedNCT02107898Phase 3
7A 52 Week Study To Assess The Use Of Bococizumab (PF-04950615; RN316) In Subjects With Heterozygous Familial HypercholesterolemiaCompletedNCT01968980Phase 3
8A Clinical Trial to Assess the Long Term Safety and Tolerability of MK-0653C in Japanese Participants With Hypercholesterolemia (MK-0653C-384)Active, not recruitingNCT02460159Phase 3
9A Clinical Trial to Assess the Long Term Safety and Tolerability of MK-0653H in Japanese Participants With Hypercholesterolemia (MK-0653H-833)Active, not recruitingNCT02748057Phase 3
10The APPROACH Study: A Study of Volanesorsen (Formerly ISIS-APOCIIIRx) in Patients With Familial Chylomicronemia SyndromeActive, not recruitingNCT02211209Phase 3
11Study To Evaluate The Effect Of Torcetrapib/Atorvastatin In Subjects With A Genetic Cholesterol Disorder.TerminatedNCT00145431Phase 3
12Efficacy and Safety Study of Eprotirome in HeFH Patients Who Are on Optimal Standard of CareTerminatedNCT01410383Phase 3
13Study to Evaluate the Effects of MBX-8025 in Patients With HoFHCompletedNCT02472535Phase 2
14Efficacy and Safety of Gemcabene in Patients With Homozygous Familial Hypercholesterolemia on Stable, Lipid-Lowering Therapy (COBALT-1)RecruitingNCT02722408Phase 2
15Trial to Evaluate the Effect of ALN-PCSSC Treatment on Low Density Lipoprotein Cholesterol (LDL-C)Active, not recruitingNCT02597127Phase 2
16DARK STUDY "DysbetalipoproteinemiA and atheRoma Risk"Unknown statusNCT01760265
17Effect of Weight Loss on Cholesterol Metabolism in Hereditary Hypercholesterolemias and Overweight or Obesity.CompletedNCT01995149
18Evaluation of LipoproteinsRecruitingNCT00001168
19The Spanish Familial Hypercholesterolaemia Cohort StudyRecruitingNCT02693548

Search NIH Clinical Center for Hyperlipoproteinemia Type Iii


Cochrane evidence based reviews: hyperlipoproteinemia type iii

Genetic Tests for Hyperlipoproteinemia Type Iii

About this section

Genetic tests related to Hyperlipoproteinemia Type Iii:

id Genetic test Affiliating Genes
1 Familial Type 3 Hyperlipoproteinemia26

Anatomical Context for Hyperlipoproteinemia Type Iii

About this section

Animal Models for Hyperlipoproteinemia Type Iii or affiliated genes

About this section

MGI Mouse Phenotypes related to Hyperlipoproteinemia Type Iii:

40
idDescriptionMGI Source AccessionScoreTop Affiliating Genes
1MP:00053708.0APOA1, APOB, APOE, HMGCR, LDLR, LPL
2MP:00053767.0APOA1, APOA5, APOB, APOE, COG2, HMGCR

Publications for Hyperlipoproteinemia Type Iii

About this section

Articles related to Hyperlipoproteinemia Type Iii:

idTitleAuthorsYear
1
Apolipoprotein E phenotyping--useful in the study of hyperlipoproteinemia type III]. (8480294)
1993
2
Normolipemic dysbetalipoproteinemia and hyperlipoproteinemia type III in subjects homozygous for a rare genetic apolipoprotein E variant (apoE1). (1973700)
1990
3
Serum and interstitial fluid apolipoprotein E levels in the healthy and in hyperlipoproteinemia type III as studied by radioimmunoassay. (4042371)
1985
4
Apolipoprotein E (role in lipoprotein metabolism and pathophysiology of hyperlipoproteinemia type III). (6283616)
1982
5
Polymorphism of apolipoprotein E. II. Genetics of hyperlipoproteinemia type III. (215360)
1979
6
Polymorphism of apolipoprotein E. I. Methodological aspects and diagnosis of hyperlipoproteinemia type III without ultracentrifugation. (215358)
1978
7
Familial hyperlipoproteinemia type III: deficiency of a specific apolipoprotein (apo E-III) in the very-low-density lipoproteins. (169165)
1975

Variations for Hyperlipoproteinemia Type Iii

About this section

Clinvar genetic disease variations for Hyperlipoproteinemia Type Iii:

5
id Gene Variation Type Significance SNP ID Assembly Location
1APOENM_000041.3(APOE): c.460C> A (p.Arg154Ser)SNVPathogenicrs121918393GRCh37Chr 19, 45412013: 45412013
2APOENM_000041.3(APOE): c.237-2A> GSNVPathogenicrs397514253GRCh37Chr 19, 45411788: 45411788
3APOENM_000041.3(APOE)duplicationPathogenicrs397514254GRCh37Chr 19, 45411968: 45411988
4APOENM_000041.3(APOE): c.490A> G (p.Lys164Glu)SNVPathogenicrs121918394GRCh37Chr 19, 45412043: 45412043
5APOENM_000041.3(APOE): c.487C> T (p.Arg163Cys)SNV, HaplotypePathogenicrs769455GRCh37Chr 19, 45412040: 45412040
6APOEAPOE, 1-BP DEL, 2919G DEL, FS60TERdeletionPathogenicChr na, -1: -1
7APOENM_000041.3(APOE): c.683G> A (p.Trp228Ter)SNVPathogenicrs121918396GRCh37Chr 19, 45412236: 45412236
8APOENM_000041.3(APOE): c.488G> A (p.Arg163His)SNVPathogenicrs121918397GRCh37Chr 19, 45412041: 45412041
9APOENM_000041.2(APOE): c.526C> T (p.Arg176Cys)SNV, Haplotypedrug responsers7412GRCh37Chr 19, 45412079: 45412079

Expression for genes affiliated with Hyperlipoproteinemia Type Iii

About this section
Search GEO for disease gene expression data for Hyperlipoproteinemia Type Iii.

Pathways for genes affiliated with Hyperlipoproteinemia Type Iii

About this section

Pathways related to Hyperlipoproteinemia Type Iii according to GeneCards Suite gene sharing:

(show all 13)
idSuper pathwaysScoreTop Affiliating Genes
19.9APOE, LDLR
29.7APOA1, APOB
3
Show member pathways
9.4APOA1, APOB, APOE
49.4HMGCR, LDLR
59.3APOA1, APOA5, APOE
69.3APOA1, APOA5, LPL
7
Show member pathways
9.0HMGCR, LDLR, LPL
8
Show member pathways
8.8APOA1, APOB, APOE, LDLR, LPL
9
Show member pathways
8.8APOA1, APOB, APOE, LDLR, LPL
10
Show member pathways
8.4APOA1, APOA5, HMGCR, LPL
11
Show member pathways
7.4APOA1, APOA5, APOB, APOE, CETP, LDLR
12
Show member pathways
6.8APOA1, APOA5, APOB, APOE, CETP, HMGCR
13
Show member pathways
6.1APOA1, APOA5, APOB, APOE, CETP, HMGCR

GO Terms for genes affiliated with Hyperlipoproteinemia Type Iii

About this section

Cellular components related to Hyperlipoproteinemia Type Iii according to GeneCards Suite gene sharing:

(show all 11)
idNameGO IDScoreTop Affiliating Genes
1intermediate-density lipoprotein particleGO:003436310.7APOB, APOE
2endocytic vesicle lumenGO:007168210.1APOA1, APOB, APOE
3low-density lipoprotein particleGO:003436210.0APOA5, APOB, APOE, LDLR
4endoplasmic reticulum lumenGO:00057889.6APOA1, APOB, LIPC
5chylomicronGO:00426279.5APOA1, APOA5, APOB, APOE, LPL
6very-low-density lipoprotein particleGO:00343619.4APOA1, APOA5, APOB, APOE, LPL
7blood microparticleGO:00725629.3APOA1, APOA5, APOE
8high-density lipoprotein particleGO:00343649.2APOA1, APOA5, APOE, CETP, LIPC
9early endosomeGO:00057699.0APOA1, APOB, APOE, LDLR, LIPC
10extracellular regionGO:00055767.6APOA1, APOA5, APOB, APOE, CETP, LIPC
11extracellular spaceGO:00056157.0APOA1, APOA5, APOB, APOE, CETP, LIPC

Biological processes related to Hyperlipoproteinemia Type Iii according to GeneCards Suite gene sharing:

(show all 40)
idNameGO IDScoreTop Affiliating Genes
1chylomicron remnant clearanceGO:003438210.5APOE, LIPC
2chylomicron remodelingGO:003437110.5LIPC, LPL
3artery morphogenesisGO:004884410.5APOB, APOE
4positive regulation of cholesterol storageGO:001088610.4APOB, LPL
5positive regulation of macrophage derived foam cell differentiationGO:001074410.3APOB, LPL
6response to carbohydrateGO:000974310.3APOB, LIPC
7regulation of Cdc42 protein signal transductionGO:003248910.3APOA1, APOE
8high-density lipoprotein particle clearanceGO:003438410.3APOA1, APOE
9regulation of intestinal cholesterol absorptionGO:003030010.3APOA1, APOA5
10positive regulation of triglyceride catabolic processGO:001089810.2APOA1, APOA5
11positive regulation of lipoprotein lipase activityGO:005100610.2APOA1, APOA5
12phosphatidylcholine metabolic processGO:004647010.2APOA5, CETP
13lipoprotein catabolic processGO:004215910.2APOB, APOE, LDLR
14cholesterol importGO:007050810.2APOA1, LDLR
15positive regulation of fatty acid biosynthetic processGO:004572310.2APOA1, APOA5
16phospholipid homeostasisGO:005509110.1APOA1, CETP
17lipoprotein biosynthetic processGO:004215810.1APOA1, APOB, APOE
18positive regulation of cholesterol esterificationGO:001087310.0APOA1, APOA5, APOE
19phospholipid effluxGO:003370010.0APOA1, APOA5, APOE
20high-density lipoprotein particle assemblyGO:003438010.0APOA1, APOA5, APOE
21lipid transportGO:00068699.9APOA5, CETP, LPA
22neuron projection regenerationGO:00311029.9APOA1, APOA5, APOE
23low-density lipoprotein particle clearanceGO:00343839.9APOB, LDLR, LIPC
24phospholipid transportGO:00159149.8APOA1, CETP, LDLR
25low-density lipoprotein particle remodelingGO:00343749.7APOB, APOE, CETP, LIPC
26very-low-density lipoprotein particle remodelingGO:00343729.7APOE, CETP, LIPC, LPL
27cholesterol effluxGO:00333449.7APOA1, APOA5, APOB, APOE
28lipid metabolic processGO:00066299.5APOB, APOE, LDLR, LPA
29high-density lipoprotein particle remodelingGO:00343759.5APOA1, APOE, CETP, LIPC
30triglyceride metabolic processGO:00066419.5APOA5, APOE, CETP, LPL
31retinoid metabolic processGO:00015239.2APOA1, APOB, APOE, LPL
32cholesterol transportGO:00303019.1APOA1, APOB, CETP, LDLR, LIPC
33reverse cholesterol transportGO:00436919.1APOA1, APOA5, APOE, CETP, LIPC
34triglyceride homeostasisGO:00703289.0APOA1, APOA5, CETP, LIPC, LPL
35cholesterol biosynthetic processGO:00066958.9APOA1, APOA5, HMGCR
36receptor-mediated endocytosisGO:00068988.7APOA1, APOB, APOE, CETP, LDLR
37triglyceride catabolic processGO:00194338.7APOA1, APOA5, APOB, APOE, LIPC, LPL
38cholesterol metabolic processGO:00082038.5APOA1, APOB, APOE, CETP, LDLR, LIPC
39lipoprotein metabolic processGO:00421578.2APOA1, APOA5, APOB, APOE, CETP, LDLR
40cholesterol homeostasisGO:00426327.9APOA1, APOA5, APOB, APOE, CETP, LDLR

Molecular functions related to Hyperlipoproteinemia Type Iii according to GeneCards Suite gene sharing:

(show all 18)
idNameGO IDScoreTop Affiliating Genes
1lipase bindingGO:003547310.5APOA5, APOB
2triglyceride bindingGO:001712910.2CETP, LPL
3low-density lipoprotein particle bindingGO:003016910.2LDLR, LIPC
4lipoprotein particle bindingGO:007181310.2APOA1, APOE
5apolipoprotein bindingGO:003418510.0LIPC, LPA, LPL
6phospholipase activityGO:000462010.0LIPC, LPL
7triglyceride lipase activityGO:000480610.0LIPC, LPL
8phospholipid transporter activityGO:000554810.0APOA1, CETP
9phosphatidylcholine-sterol O-acyltransferase activator activityGO:006022810.0APOA1, APOA5, APOE
10beta-amyloid bindingGO:00015409.8APOA1, APOE
11lipid transporter activityGO:00053199.8APOA1, APOE, CETP
12phosphatidylcholine bindingGO:00312109.6APOA1, APOA5, CETP
13low-density lipoprotein particle receptor bindingGO:00507509.6APOA5, APOB, APOE
14cholesterol bindingGO:00154859.4APOA1, APOA5, APOE, CETP
15phospholipid bindingGO:00055439.1APOA1, APOA5, APOB, APOE
16cholesterol transporter activityGO:00171279.1APOA1, APOA5, APOB, APOE, CETP
17heparin bindingGO:00082018.9APOA5, APOB, APOE, LIPC, LPA, LPL
18lipid bindingGO:00082898.0APOA1, APOA5, APOB, APOE, CETP, LIPC

Sources for Hyperlipoproteinemia Type Iii

About this section
2CDC
6CNVD
10DGIdb
15ExPASy
16FDA
17FMA
26GTR
27HGMD
28HMDB
29ICD10
30ICD10 via Orphanet
31ICD9CM
32IUPHAR
33KEGG
36MedGen
38MeSH
39MESH via Orphanet
40MGI
43NCI
44NCIt
45NDF-RT
48NINDS
49Novoseek
51OMIM
52OMIM via Orphanet
56PubMed
57QIAGEN
62SNOMED-CT via Orphanet
66Tumor Gene Family of Databases
67UMLS
68UMLS via Orphanet